Radiology and nuclear medicine practices are also changing as we expand beyond diagnostic imaging to include more longitudinal therapeutic care to our patients through the administration of radium 223 to our castrate resistant patients with symptomatic bone metastases.Patient involvement in health policy, clinical care, and research has gained momentum in recent years.
With regards to imaging, the advances in therapy have created an urgent need to develop better technologies to detect and monitor metastatic disease. For example, urologists have become more actively involved in the management of castrate resistant prostate cancer patients. The several new therapies recently approved for the treatment of metastatic castrate resistant prostate cancer patients have altered the roles of various healthcare providers practicing in this space. The Changing Role of the Radiologist/Nuclear Medicine Physician in the Management of Advanced Prostate Cancer Patients - EVERYDAY UROLOGY- Full text articleĠ4 October 2016 Published in Everyday Urology - Oncology Insights: Volume 1, Issue 1 Published Date: March, 2016 In the following article, he reflects on the highlights of the COU-AA-302 journey, including the pioneering results and methodology of the study, as well as the voice of the study results including the secondary endpoints on patient outcomes such as pain, time to opiate use, and functional status.
Ryan is Professor of Clinical Medicine and Urology and Thomas Perkins Distinguished Professor in Cancer Research, and Program Leader, Genitourinary Medical Oncology at the University of California-San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, CA. The Story of the COU-AA-302 Clinical Trial: Highlights From the Journey - Full-Text Articleġ7 November 2016 Published in Everyday Urology - Oncology Insights: Volume 1, Issue 2 Published Date: June 2016Ĭharles J Ryan, MD, is a leader in medical oncology and was the primary investigator for the COU-AA-302 clinical trial, which led to FDA approval of abiraterone acetate plus prednisone as the first oral therapy for treatment in chemotherapy-naïve metastatic castration-resistant prostate cancer.
0 kommentar(er)
